Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include muscle spasms; seizures.
Proper storage of Ceftriaxone Choongwae:
Ceftriaxone Choongwae is usually handled and stored by a health care provider. If you are using Ceftriaxone Choongwae at home, store Ceftriaxone Choongwae as directed by your pharmacist or health care provider. Keep Ceftriaxone Choongwae, as well as needles and syringes, out of the reach of children and away from pets.
Overdose of Ceftriaxone Choongwae in details
When a dose is taken in higher dose than the recommended doses, it is called Overdose. Overdose always needs a clinical supervision. Any medicine or drug when consumed in Overdose produces untoward side effects on one or various organs in the body. A medicine is excreted in the kidney or metabolized in the liver most of the times. This process goes without any hurdles when taken in normal dose, but when taken in an overdose, the body is not able to metabolize it or send it out properly which causes the effects of anoverdose.
sponsored
In the case of overdose, nausea, vomiting and diarrhea can occur. Ceftriaxone Choongwae concentration can not be reduced by hemodialysis or peritoneal dialysis.
There is no specific antidote. Treatment is symptomatic.
What should I avoid while taking Ceftriaxone Choongwae?
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or has blood in it, call your doctor. Do not use any medicine to stop the diarrhea unless your doctor has told you to.
Ceftriaxone Choongwae warnings
Warnings are a mix of Precautions. Contraindications and interactions and serious harmful effects associated with the medicine intake. A diabetic or Hypertensive patient need to be warned about few drug interactions. A known hypersensitivity patient needs to be careful about the reactions or anaphylactic shock. A pregnant woman or a breastfeeding woman should be warned of certain medications. A Hepatitis [liver disease] patient or a cardiac patient should avoid few drugs.
Hypersensitivity Reactions
Before therapy with Ceftriaxone Choongwae is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins and other beta-lactam agentsor other drugs. This product should be given cautiously to penicillin and other beta-lactam agent-sensitive patients. Antibacterial drugs should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. Serious acute hypersensitivity reactions may require the use of subcutaneous epinephrine and other emergency measures.
As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions (i.e., anaphylaxis) have been reported. In case of severe hypersensitivity reactions, treatment with Ceftriaxone Choongwae must be discontinued immediately and adequate emergency measures must be initiated.
Interaction With Calcium-Containing Products
Do not use diluents containing calcium, such as Ringer's solution or Hartmann's solution, to reconstitute Ceftriaxone Choongwae vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of Ceftriaxone Choongwae-calcium can also occur when Ceftriaxone Choongwae is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone Choongwae must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone Choongwae and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of Ceftriaxone Choongwae-calcium.
Clostridium Difficile -Associated Diarrhea
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Ceftriaxone Choongwae, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Hemolytic Anemia
An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including Ceftriaxone Choongwae. Severe cases of hemolytic anemia, including fatalities, have been reported during treatment in both adults and children. If a patient develops anemia while on Ceftriaxone Choongwae, the diagnosis of a cephalosporin associated anemia should be considered and Ceftriaxone Choongwae stopped until the etiology is determined.
What should I discuss with my healthcare provider before taking Ceftriaxone Choongwae?
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For Ceftriaxone Choongwae, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to Ceftriaxone Choongwae or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of Ceftriaxone Choongwae in children. Because of Ceftriaxone Choongwae's toxicity, use in newborn and premature babies is not recommended.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Ceftriaxone Choongwae in the elderly.
Pregnancy
Pregnancy Category
Explanation
All Trimesters
B
Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus.
Breast Feeding
Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.
Interactions with Medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving Ceftriaxone Choongwae, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using Ceftriaxone Choongwae with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Calcium Acetate
Calcium Chloride
Calcium Gluceptate
Calcium Gluconate
Lactated Ringer's Solution
Ringer's Solution
Using Ceftriaxone Choongwae with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Warfarin
Interactions with Food/Tobacco/Alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
Other Medical Problems
The presence of other medical problems may affect the use of Ceftriaxone Choongwae. Make sure you tell your doctor if you have any other medical problems, especially:
Anemia or
Diarrhea or
Gallbladder disease or
Pancreatitis (inflammation of the pancreas) or
Stomach or bowel disease (e.g., colitis), history of—Use with caution. May make these conditions worse.
Hyperbilirubinemia (high bilirubin in the blood)—Should not be used in newborn (less than 28 days of age) and premature infants with this condition.
Kidney disease or
Liver disease—Use with caution. Effects may be increased because of slower removal of the medicine from the body.
Liver disease, severe or
Undernourished condition—May be worsened by Ceftriaxone Choongwae and you may need to take Vitamin K.
Ceftriaxone Choongwae precautions
Certain people who are very sick or very old or who are sensitive show an exacerbation of side effect of the drug which can turn dangerous at times. So, it is very important to remember the precautions while taking the medicine. Pregnancy and Breastfeeding are also special categories wherein extra care or precaution is needed when taking a drug. Few patients may have a hypersensitivity reaction to few medications, and that can be life-threatening rarely. Penicillin hypersensitivity is one example. Diarrhea, rashes are few other symptoms which need a watch. A patient with other co-existing diseases like liver disease, heart disease, kidney disease should take special precautions.
sponsored
General: Prescribing B Braun Ceftriaxone Choongwae in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Although transient elevations of blood urea nitrogen (BUN) and serum creatinine have been observed, at the recommended dosages, the nephrotoxic potential of Ceftriaxone Choongwae sodium is similar to that of other cephalosporins.
Ceftriaxone Choongwae is excreted via both biliary and renal excretion. Therefore, patients with renal failure normally require no adjustment in dosage when usual doses of B Braun Ceftriaxone Choongwae are administered, but concentrations of drug in the serum should be monitored periodically. If evidence of accumulation exists, dosage should be decreased accordingly.
Dosage adjustments should not be necessary in patients with hepatic dysfunction; however, in patients with both hepatic dysfunction and significant renal disease, B Braun Ceftriaxone Choongwae dosage should not exceed 2 g daily without close monitoring of serum concentrations.
Alterations in prothrombin times have occurred rarely in patients treated with Ceftriaxone Choongwae sodium. Patients with impaired vitamin K synthesis or low vitamin K stores (eg, chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during B Braun Ceftriaxone Choongwae treatment. Vitamin K administration (10 mg weekly) may be necessary if the prothrombin time is prolonged before or during therapy.
Prolonged use of B Braun Ceftriaxone Choongwae may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
B Braun Ceftriaxone Choongwae should be prescribed with caution in individuals with a history of gastrointestinal disease, especially colitis.
There have been reports of sonographic abnormalities in the gallbladder of patients treated with Ceftriaxone Choongwae sodium; some of these patients also had symptoms of gallbladder disease. These abnormalities appear on sonography as an echo without acoustical shadowing suggesting sludge or as an echo with acoustical shadowing which may be misinterpreted as gallstones. The chemical nature of the sonographically detected material has been determined to be predominantly a Ceftriaxone Choongwae-calcium salt. The condition appears to be transient and reversible upon discontinuation of Ceftriaxone Choongwae sodium and institution of conservative management. Therefore, B Braun Ceftriaxone Choongwae should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease and/or the sonographic findings described previously.
Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with Ceftriaxone Choongwae sodium. Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition). A cofactor role of Ceftriaxone Choongwae-related biliary precipitation cannot be ruled out.
The elimination of Ceftriaxone Choongwae is not altered by probenecid.
As with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient history is taken.
As with other dextrose-containing solutions, B Braun Ceftriaxone Choongwae should be prescribed with caution in patients with overt or known subclinical diabetes mellitus or carbohydrate intolerance for any reason.
If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.
Use only if solution is clear and container and seals are intact.
Information for Patients: Patients should be counseled that antibacterial drugs including B Braun Ceftriaxone Choongwae should only be used to treat bacterial infections. They do not treat viral infections (eg, the common cold). When B Braun Ceftriaxone Choongwae is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may decrease the effectiveness of the immediate treatment and increase the likelihood that bacteria will develop resistance and will not be treatable by B Braun Ceftriaxone Choongwae or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as ≥2 months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Carcinogenicity: Considering the maximum duration of treatment and the class of the compound, carcinogenicity studies with Ceftriaxone Choongwae in animals have not been performed. The maximum duration of animal toxicity studies was 6 months.
Mutagenicity: Genetic toxicology tests included the Ames test, a micronucleus test and a test for chromosomal aberrations in human lymphocytes cultured in vitro with Ceftriaxone Choongwae. Ceftriaxone Choongwae showed no potential for mutagenic activity in these studies.
Impairment of Fertility: Ceftriaxone Choongwae produced no impairment of fertility when given IV to rats at daily doses up to 586 mg/kg/day approximately 20 times the recommended clinical dose of 2 g/day.
Use in pregnancy:Teratogenic Effects: Pregnancy Category B. Reproductive studies have been performed in mice and rats at doses up to 20 times the usual human dose and have no evidence of embryotoxicity, fetotoxicity or teratogenicity. In primates, no embryotoxicity or teratogenicity was demonstrated at a dose approximately 3 times the human dose.
There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, B Braun Ceftriaxone Choongwae should be used during pregnancy only if clearly needed.
Nonteratogenic Effects: In rats, in the Segment I (fertility and general reproduction) and Segment III (perinatal and postnatal) studies with IV administered Ceftriaxone Choongwae, no adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior and reproductive ability of the offspring, at doses of ≤586 mg/kg/day.
Use in lactation: Low concentrations of Ceftriaxone Choongwae are excreted in human milk. Caution should be exercised when B Braun Ceftriaxone Choongwae is administered to a nursing woman.
Use in children: B Braun Ceftriaxone Choongwae in the Duplex container is designed to deliver a 1 or 2 g dose of Ceftriaxone Choongwae. To prevent unintentional overdose, B Braun Ceftriaxone Choongwae should not be used in pediatric patients who require less than the full adult dose of Ceftriaxone Choongwae.
Safety and effectiveness of B Braun Ceftriaxone Choongwae in neonates, infants and pediatric patients have been established for the dosages described in the Dosage & Administration. In vitro studies have shown that Ceftriaxone Choongwae, like some other cephalosporins, can displace bilirubin from serum albumin. B Braun Ceftriaxone Choongwae should not be administered to hyperbilirubinemic neonates, especially prematures.
Use in the
Elderly: Of the total number of subjects in clinical studies of Ceftriaxone Choongwae sodium, 32% were ≥60 years. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
The pharmacokinetics of Ceftriaxone Choongwae were only minimally altered in geriatric patients compared to healthy adult subjects and dosage adjustments are not necessary for geriatric patients with Ceftriaxone Choongwae dosages up to 2 g/day.
No dosage adjustment is necessary for patients with impairment of renal or hepatic function; however, blood levels should be monitored in patients with severe renal impairment (eg, dialysis patients) and in patients with both renal and hepatic dysfunctions.
What happens if I miss a dose of Ceftriaxone Choongwae?
When you miss a dose, you should take it as soon as you remember, but you should take care that it should be well spaced from the next dose. You should not take an extra dose at the time of the second dose as it will become a double dose. The double dose can give unwanted side effects, so be careful. In chronic conditions or when you have a serious health issue, if you miss a dose, you should inform your health care provider and ask his suggestion.
Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.
sponsored
References
DailyMed. "CEFTRIAXONE SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
